[4]Chen J.J.,Jin Z.C.,Luo B.,et al.New first-line immunotherapy-based therapies for unresectable hepatocellular carcinoma:a living network meta-analysis.J Clin Transl Hepatol.2024;12(1):15–24. [5]Zhou J,Sun H,W...
参考资料: [1]Galle PR, Decaens T, Kudo M, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from Ch...
First-Line Therapy for Advanced HCC: The Role of TKIs and ICIs Academic Perspectives on Systemic Therapy for Advanced uHCC Considerations for Treatment Approaches in Intermediate-Stage HCC Navigating the Evolving First-Line Treatment Regimens in Intermediate-Stage HCC Optimizing Frontline TKI Therapy in...
13.Vogel A, Qin S, Kudo M, et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;6(8):649-658. doi:10.1016/S2468-1253(21...
First line treatment in CPB: Sorafenib (86%), Nivolumab (8%), Lenvatinib (6%). Sorafenib was used across all ALBI grades, while Lenvatinib and Nivolumab were given only in ALBI II (Table).Conclusions:Sorafenib was more often given to patients with CPB cirrhosis, in the first line setting;...
参考文献:Feng, M.Y.; Chan, L.L.; Chan, S.L. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Curr. Oncol. 2022, 29, 5489-5507. 声明:本资料中涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见或指导。
The combination of Opdivo and Yervoy is also approved for metastatic melanoma, first-line treatment of adult patients with metastatic non-small cell lung cancer, first-line treatment of adult patients with unresectable malignant pleural mesothelioma and first-line treatment of adult patients with interme...
Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: a phase 3, multicenter, randomized controlled trial. 2022 Gastrointestinal Cancers Symposium; January 20-22, 2022; Virtual. Abstract 380. ...
[11]Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet.2018;391(10126):1163–73. ...
EP: 11.Novel First-Line Immunotherapy Approaches in Advanced HCC EP: 12.Treatment Options for Advanced HCC in the Second-Line and Beyond EP: 13.Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line EP: 14.Management of Hepatocellular Carcinoma: Future Directions in Care Trans...